NCT03406858View on ClinicalTrials.gov

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

January 20, 2021

Study Completion Date

November 7, 2022

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaProstate Carcinoma Metastatic in the BonePSA ProgressionStage IV Prostate Adenocarcinoma AJCC v7
Interventions
BIOLOGICAL

HER2Bi-Armed Activated T Cells

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT03406858 - Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter